To include your compound in the COVID-19 Resource Center, submit it here.

LJP 394: Phase II/III data; Phase III

In a subset of 27 patients with poor renal function in the company's Phase II/III trial, LJPC said

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE